ClinicalTrials.gg
TerminatedNCT04374136Updated Sep 21, 2026Results posted

A Phase 3 Study to Evaluate Efficacy and Safety of AL001 in Frontotemporal Dementia (INFRONT-3)

A Phase 3 interventional study of Part 1 Blinded - AL001 and Part 1 Blinded - Placebo in Frontotemporal Dementia, sponsored by Alector Inc.. Terminated at 44 sites in 16 countries. Open to participants aged 25 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-09-21.

Sponsored by Alector Inc. · Phase 3, Interventional, and Treatment

Why this study was terminated
The trial did not meet the clinical co-primary endpoint of slowing FTD-GRN progression, as measured by the Clinical Dementia Rating® plus National Alzheimer's Coordinating Center Frontotemporal Lobar Degeneration Sum of Boxes (CDR® plus NACC FTLD-SB)

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
119
Allocation
Randomized
Ages
25 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 103 studies in Frontotemporal Dementia with a site in United States — 31 open to participants now, 45 under way, none of them phase 3. Frontotemporal Dementia · United States.

Enrollment
21st of 66
119 · median 60
Started
2020
with 7 others
Phase 3
5 of 103
none open now
Registered
60th of 103
by date
Lead sponsor
4 of 103
Alector Inc.

Among the 103 studies in Frontotemporal Dementia with a site in United States, this one is the 21st largest by enrollment of the 66 interventional ones that give a count, is one of 8 that started in 2020, is one of 5 in phase 3, and was the 60th registered.

Frontotemporal Dementia

208 studies on the registry are indexed under Frontotemporal Dementia; 72 are open to participants now.

Browse Frontotemporal Dementia studies →

Open to participants now

31 of the 103 studies in Frontotemporal Dementia with a site in United States are open now. Recruiting first, the newest first:

26 more — sign in →

All 31 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 51 Frontotemporal Dementia studies recruiting now, 29 (57%) set no upper age limit and 5 (10%) stop at 75 or younger; 6 take children under 18; 30 take healthy volunteers.

This study: 25 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 103 studies in Frontotemporal Dementia with a site in United States, or all of them as a file.
02

Study summary

A phase 3 double blind, placebo controlled study evaluating the efficacy and safety of AL001 in participants at risk for or with frontotemporal dementia due to heterozygous mutations in the progranulin gene.

Read the detailed description

This is a phase 3 double blind, placebo controlled study evaluating the efficacy and safety of AL001 administered intravenously in participants at risk for or with frontotemporal dementia due to heterozygous mutations in the progranulin gene. Study completion marks the end of the open label extension period following the 96-week blinded portion of the study.

03

Conditions studied

  • Frontotemporal Dementia
04

Who can participate

Ages eligible
25 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Persons with a progranulin gene mutation and at risk of developing FTD symptoms as evidenced by a biomarker, or persons with a progranulin gene mutation and diagnosed with FTD.
  • If symptomatic, one or more of the criteria for the diagnosis of possible behavioral variant FTD, or a diagnosis of Primary Progressive Aphasia.
  • Study partner who consents to study participation and who cares for/visits the participant daily for at least 5 hours per week.
  • Written must be obtained and documented (from the participant or, where jurisdictions allow it, from their legal decision maker).

Exclusion criteria

Exclusion Criteria:

  • Dementia due to a condition other than FTD including, but not limited to, Alzheimer's disease, Parkinson's disease, dementia with Lewy bodies, Huntington disease, or vascular dementia.
  • Known history of severe allergic, anaphylactic, or other reactions to chimeric, human, or humanized antibodies or fusion proteins.
  • Current uncontrolled hypertension, diabetes mellitus or thyroid disease. heart disease, liver disease or kidney disease. History or evidence of clinically significant brain disease other than FTD.
  • Females who are pregnant or breastfeeding, or planning to conceive within the study period.
  • Any experimental vaccine or gene therapy.
  • History of cancer, unless in remission or stable/adequately controlled.
  • Current use of anticoagulant medications (e.g., coumadin, heparinoids, apixaban).
  • Residence in a skilled nursing facility, convalescent home, or long term care facility at screening; or requires continuous nursing care.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
119 participants (actual)

Study arms

  • Experimental
    Part 1 Blinded - AL001

    Participants receive AL001 60 mg/kg administered by intravenous (IV) infusion every 4 weeks during the double-blind treatment period.

    Drug: Part 1 Blinded - AL001

  • Placebo comparator
    Part 1 Blinded - Placebo

    Participants receive placebo administered by intravenous (IV) infusion every 4 weeks during the double-blind treatment period.

    Drug: Part 1 Blinded - Placebo

  • Experimental
    Part 2 (OLE Treatment) - AL001

    Participants who received AL001 during the double-blind treatment period and enroll in the optional open-label extension receive AL001 60 mg/kg administered by intravenous (IV) infusion every 4 weeks.

    Drug: Part 2 (OLE Treatment) - AL001

  • Experimental
    Part 2 (OLE Treatment) - Placebo Switched to AL001

    Participants who received placebo during the double-blind treatment period and enroll in the optional open-label extension receive AL001 60 mg/kg administered by intravenous (IV) infusion every 4 weeks.

    Drug: Part 2 (OLE Treatment) - Placebo Switched to AL001

Interventions

  • DrugPart 1 Blinded - AL001

    Administered via intravenous (IV) infusion

  • DrugPart 1 Blinded - Placebo

    Administered via intravenous (IV) infusion

  • DrugPart 2 (OLE Treatment) - AL001

    Administered via intravenous (IV) infusion

  • DrugPart 2 (OLE Treatment) - Placebo Switched to AL001

    Administered via intravenous (IV) infusion

06

What researchers measure

Primary outcomes

  1. Part 1 Double Blind - Evaluation of Efficacy of AL001 Compared With Placebo as Measured by the CDR® Plus NACC FTLD-SB in Symptomatic Patients

    Part 1 Primary Endpoint - Change from baseline to Weeks 48, 72, and 96 in the CDR® plus NACC FTLD-SB. The Clinical Dementia Rating Dementia Staging Instrument PLUS National Alzheimer's Disease Coordinating Center frontotemporal lobar degeneration Behavior \& Language Domains Sum of Boxes (CDR® plus NACC FTLD-SB) is administered by a healthcare professional and based on individual ratings of the eight domains: memory, orientation, judgment and problem solving, community affairs, home and hobbies, personal care, language and behavior. Impairment is scored on a scale in which none = 0, questionable = 0.5, mild = 1, moderate = 2 and severe = 3. The 8 individual domain ratings, or "box scores", were added together to give the CDR® plus NACC FTLD-SB which ranges from 0-24. Higher score indicates severe impairment.

    Time frame: Through study completion, on average up to 96 weeks

  2. Part 1 Double Blind (Co-Primary US Endpoint) - Evaluation of the Treatment Effect of AL001 Compared With Placebo as Measured by Pharmacodynamic and Disease Pathology Biomarkers in Symptomatic Patients

    Geometric Mean Fold Change from baseline to Week 96 in PGRN concentrations in plasma

    Time frame: Baseline to 96 weeks

  3. Part 2 OLE - To Assess the Long-term Safety and Tolerability of AL001 in Participants Who Have Completed Part 1 of the Study

    Part 2 OLE Primary Endpoint - Incidence, nature, and severity of AEs and SAEs in Part 2 OLE

    Time frame: 96 weeks

Secondary outcomes

  1. Part 1 Double Blind - Evaluation of Efficacy of AL001 Compared With Placebo in Symptomatic Participants as Measured by CGI-S

    Change from baseline to Weeks 48, 72, and 96 on the CGI-S. The CGI-S is used by a clinician to rate the severity of a participant's disease relative to the clinician's past experience with patients who have the same disease using an ordinal scale ranging from 1=normal, not at all ill; 2=borderline ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; and 7=among the most extremely ill patients. Higher scores indicate worsening.

    Time frame: Baseline to 96 weeks

  2. Part 1 Double Blind - Evaluation of Efficacy of AL001 Compared With Placebo in Symptomatic Participants as Measured by CGI-I

    Actual values at Weeks 48, 72, and 96 on the CGI-I. The CGI-I is used by a clinician to rate how much a participant's disease has improved or worsened relative to baseline using an ordinal scale ranging from 1=very much improved; 2=much improved; 3=minimally improved; 4=no change from baseline; 5=minimally worse; 6= much worse; and 7=very much worse. Higher scores indicate worsening.

    Time frame: Baseline to 96 weeks

  3. Part 1 Double Blind - Evaluation of Efficacy of AL001 Compared With Placebo in Symptomatic Participants as Measured by Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) Score

    Change from baseline to Weeks 48, 72, and 96 on the RBANS. RBANS is 20 to 25 minute battery developed for cognitive assessment, detection, and characterization of dementia. RBANS includes 12 subtests that measure following 5 indices: (1)Attention Index, composed of Digit Span and Coding; (2)Language Index, consisting of Picture Naming and Semantic Fluency subtests; (3)Visuospatial/Construction Index, made up of Figure Copy and Line Orientation subtests; (4)Immediate Memory Index, composed of List Learning and Story Memory subtests, and (5)Delayed Memory Index, consisting of List Recall, List Recognition, Story Recall, and Figure Recall subtests. Completion of RBANS yields 5 index scores based on participant performance on various subtests, as well as a composite Total Index score for battery. Total index scores range from 40 to 160, and are normalized to a mean of 100 and standard deviation (SD) of 15. Higher scores indicate less impairment.

    Time frame: Baseline to 96 weeks

  4. Part 1 Double Blind - Evaluation of the Safety and Tolerability of AL001 Compared With Placebo as Measured by Safety Assessments

    Incidence of adverse events

    Time frame: Baseline to 96 weeks

  5. Part 1 Double Blind: Clinical Progression as Measured by Frontotemporal Dementia Rating Scale (FRS) Logit Score in Symptomatic Participants

    The FRS is a 30-item scale with item responses of 'All the time,' 'Sometimes,' 'Never,' or 'Not applicable' for each item. The total percentage score is calculated as the number of items with a response of 'Never,' divided by the number of applicable items, excluding those marked 'not applicable.' The percentage score ranges from 0 to 100, inclusive, with higher scores indicating better function (fewer behavioral/functional problems) and lower scores indicating worse function. The percentage score is converted to a logit score ranging from -6.66 to 5.39 using a look-up table defined as part of the FRS instrument, where a higher (more positive) logit score indicates better function/less disease severity (5.39 = normal) and a lower (more negative) logit score indicates worse function/greater disease severity (-6.66 = advanced/profound impairment). A decrease in logit score over time reflects clinical progression

    Time frame: baseline to 96 weeks

07

Results

Posted Sep 21, 2026

Participant flow

Approximately 110 participants were to be enrolled, with a minimum of 90 symptomatic participants. A total of 119 participants were randomized: 103 participants were symptomatic, and 16 participants were non-symptomatic and thus considered "at-risk". In Part 1, participants were randomly assigned to receive latozinemab (60 mg/kg) or placebo in a 3:2 ratio (latozinemab:placebo). In Part 2, all participants received latozinemab 60 mg/kg q4w, regardless of treatment assignment in Part 1.

Period 1 - Blinded
Participant flow — Period 1 - Blinded
MilestonePart 1 Blinded - AL001Part 1 Blinded - PlaceboPart 2 (OLE Treatment) - AL001Part 2 (OLE Treatment) - Placebo Switched to AL001
Started724700
Completed403500
Not completed321200
Withdrew: Adverse event3000
Withdrew: Lost to follow-up1000
Withdrew: Physician decision1200
Withdrew: Withdrawal by subject20600
Withdrew: Study terminated by sponsor2000
Withdrew: Protocol deviation1000
Withdrew: Death2000
Withdrew: Randomized not dosed0100
Withdrew: Progressive disease1200
Withdrew: Other1100
Period 2 - Open Label Extension
Participant flow — Period 2 - Open Label Extension
MilestonePart 1 Blinded - AL001Part 1 Blinded - PlaceboPart 2 (OLE Treatment) - AL001Part 2 (OLE Treatment) - Placebo Switched to AL001
Started003528
Completed00108
Not completed002520
Withdrew: Physician decision0011
Withdrew: Withdrawal by subject0065
Withdrew: Death0010
Withdrew: Study terminated by sponsor001614
Withdrew: Other0010

Outcome measures

PrimaryPart 1 Double Blind - Evaluation of Efficacy of AL001 Compared With Placebo as Measured by the CDR® Plus NACC FTLD-SB in Symptomatic Patients

Part 1 Primary Endpoint - Change from baseline to Weeks 48, 72, and 96 in the CDR® plus NACC FTLD-SB. The Clinical Dementia Rating Dementia Staging Instrument PLUS National Alzheimer's Disease Coordinating Center frontotemporal lobar degeneration Behavior \& Language Domains Sum of Boxes (CDR® plus NACC FTLD-SB) is administered by a healthcare professional and based on individual ratings of the eight domains: memory, orientation, judgment and problem solving, community affairs, home and hobbies, personal care, language and behavior. Impairment is scored on a scale in which none = 0, questionable = 0.5, mild = 1, moderate = 2 and severe = 3. The 8 individual domain ratings, or "box scores", were added together to give the CDR® plus NACC FTLD-SB which ranges from 0-24. Higher score indicates severe impairment.

Time frame:
Through study completion, on average up to 96 weeks
Reported as:
Least squares mean · score on the scale
Part 1 Double Blind - Evaluation of Efficacy of AL001 Compared With Placebo as Measured by the CDR® Plus NACC FTLD-SB in Symptomatic Patients
score on the scalePart 1 Blinded - AL001Part 1 Blinded - Placebo
Week 96 Change from Baseline9.686 (7.938 to 11.433)8.177 (6.469 to 9.885)
Week 72 Change from Baseline6.765 (5.592 to 7.939)5.771 (4.623 to 6.919)
Week 48 Change from Baseline4.477 (3.617 to 5.337)4.628 (3.702 to 5.553)
Statistical analysis
  • Part 1 Blinded - AL001 vs Part 1 Blinded - Placebo · Mixed Models Analysis · p = 0.2278 · Mean difference (final values): 1.509 · 95% CI -0.959 to 3.976
SecondaryPart 1 Double Blind - Evaluation of Efficacy of AL001 Compared With Placebo in Symptomatic Participants as Measured by CGI-S

Change from baseline to Weeks 48, 72, and 96 on the CGI-S. The CGI-S is used by a clinician to rate the severity of a participant's disease relative to the clinician's past experience with patients who have the same disease using an ordinal scale ranging from 1=normal, not at all ill; 2=borderline ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; and 7=among the most extremely ill patients. Higher scores indicate worsening.

Time frame:
Baseline to 96 weeks
Reported as:
Least squares mean · score on the scale
Part 1 Double Blind - Evaluation of Efficacy of AL001 Compared With Placebo in Symptomatic Participants as Measured by CGI-S
score on the scalePart 1 Blinded - AL001Part 1 Blinded - Placebo
Change from Baseline to Week 961.593 (1.297 to 1.888)1.450 (1.170 to 1.730)
Change from Baseline to Week 721.285 (1.049 to 1.521)1.176 (0.878 to 1.474)
Change from Baseline to Week 481.019 (0.835 to 1.202)0.776 (0.558 to 0.994)
SecondaryPart 1 Double Blind - Evaluation of Efficacy of AL001 Compared With Placebo in Symptomatic Participants as Measured by CGI-I

Actual values at Weeks 48, 72, and 96 on the CGI-I. The CGI-I is used by a clinician to rate how much a participant's disease has improved or worsened relative to baseline using an ordinal scale ranging from 1=very much improved; 2=much improved; 3=minimally improved; 4=no change from baseline; 5=minimally worse; 6= much worse; and 7=very much worse. Higher scores indicate worsening.

Time frame:
Baseline to 96 weeks
Reported as:
Least squares mean · score on the scale
Part 1 Double Blind - Evaluation of Efficacy of AL001 Compared With Placebo in Symptomatic Participants as Measured by CGI-I
score on the scalePart 1 Blinded - AL001Part 1 Blinded - Placebo
Week 965.734 (5.461 to 6.007)5.530 (5.254 to 5.806)
Week 725.373 (5.095 to 5.651)5.285 (5.077 to 5.492)
Week 485.201 (5.001 to 5.401)5.167 (4.949 to 5.385)
SecondaryPart 1 Double Blind - Evaluation of Efficacy of AL001 Compared With Placebo in Symptomatic Participants as Measured by Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) Score

Change from baseline to Weeks 48, 72, and 96 on the RBANS. RBANS is 20 to 25 minute battery developed for cognitive assessment, detection, and characterization of dementia. RBANS includes 12 subtests that measure following 5 indices: (1)Attention Index, composed of Digit Span and Coding; (2)Language Index, consisting of Picture Naming and Semantic Fluency subtests; (3)Visuospatial/Construction Index, made up of Figure Copy and Line Orientation subtests; (4)Immediate Memory Index, composed of List Learning and Story Memory subtests, and (5)Delayed Memory Index, consisting of List Recall, List Recognition, Story Recall, and Figure Recall subtests. Completion of RBANS yields 5 index scores based on participant performance on various subtests, as well as a composite Total Index score for battery. Total index scores range from 40 to 160, and are normalized to a mean of 100 and standard deviation (SD) of 15. Higher scores indicate less impairment.

Time frame:
Baseline to 96 weeks
Reported as:
Least squares mean · score on the scale
Part 1 Double Blind - Evaluation of Efficacy of AL001 Compared With Placebo in Symptomatic Participants as Measured by Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) Score
score on the scalePart 1 Blinded - AL001Part 1 Blinded - Placebo
Change from Baseline to Week 96-10.578 (-17.240 to -3.917)-8.012 (-12.038 to -3.986)
Change from Baseline to Week 72-9.707 (-14.773 to -4.642)-10.625 (-14.007 to -7.243)
Change from Baseline to Week 48-10.077 (-12.531 to -7.623)-11.359 (-15.306 to -7.412)
PrimaryPart 1 Double Blind (Co-Primary US Endpoint) - Evaluation of the Treatment Effect of AL001 Compared With Placebo as Measured by Pharmacodynamic and Disease Pathology Biomarkers in Symptomatic Patients

Geometric Mean Fold Change from baseline to Week 96 in PGRN concentrations in plasma

Time frame:
Baseline to 96 weeks
Reported as:
Geometric least squares mean · Fold Change
Part 1 Double Blind (Co-Primary US Endpoint) - Evaluation of the Treatment Effect of AL001 Compared With Placebo as Measured by Pharmacodynamic and Disease Pathology Biomarkers in Symptomatic Patients
Fold ChangePart 1 Blinded - AL001Part 1 Blinded - Placebo
Part 1 Double Blind (Co-Primary US Endpoint) - Evaluation of the Treatment Effect of AL001 Compared With Placebo as Measured by Pharmacodynamic and Disease Pathology Biomarkers in Symptomatic Patients2.267 (2.097 to 2.451)0.857 (0.784 to 0.937)
Statistical analysis
  • Part 1 Blinded - AL001 vs Part 1 Blinded - Placebo · Mixed Models Analysis · p = <.0001 · Geometric mean ratio of fold change: 2.645 · 95% CI 2.351 to 2.976Geometric mean fold change from baseline
SecondaryPart 1 Double Blind - Evaluation of the Safety and Tolerability of AL001 Compared With Placebo as Measured by Safety Assessments

Incidence of adverse events

Time frame:
Baseline to 96 weeks
Reported as:
Number · participants
Part 1 Double Blind - Evaluation of the Safety and Tolerability of AL001 Compared With Placebo as Measured by Safety Assessments
participantsPart 1 Blinded - AL001Part 1 Blinded - Placebo
Any TEAE6240
TEAE graded as Severe or higher114
Any Treatment-Emergent Serious AE (TESAE)113
TEAE Leading to Early Study Treatment Discontinuation41
TEAE Leading to Study Treatment Interruption62
TEAE Leading to Death20
Any Treatment-related TEAE1811
Treatment-Related TEAE graded as Severe or higher11
Any Treatment-Related TESAE10
PrimaryPart 2 OLE - To Assess the Long-term Safety and Tolerability of AL001 in Participants Who Have Completed Part 1 of the Study

Part 2 OLE Primary Endpoint - Incidence, nature, and severity of AEs and SAEs in Part 2 OLE

Time frame:
96 weeks
Reported as:
Number · events
Part 2 OLE - To Assess the Long-term Safety and Tolerability of AL001 in Participants Who Have Completed Part 1 of the Study
eventsPart 2 (OLE Treatment) - AL001Part 2 (OLE Treatment) - Placebo Switched to AL001
Any TEAE2817
TEAE graded as Severe or higher24
Any Treatment-Emergent Serious AE (TESAE)22
TEAE Leading to Early Study Treatment Discontinuation00
TEAE Leading to Study Treatment Interruption14
TEAE Leading to Death10
SecondaryPart 1 Double Blind: Clinical Progression as Measured by Frontotemporal Dementia Rating Scale (FRS) Logit Score in Symptomatic Participants

The FRS is a 30-item scale with item responses of 'All the time,' 'Sometimes,' 'Never,' or 'Not applicable' for each item. The total percentage score is calculated as the number of items with a response of 'Never,' divided by the number of applicable items, excluding those marked 'not applicable.' The percentage score ranges from 0 to 100, inclusive, with higher scores indicating better function (fewer behavioral/functional problems) and lower scores indicating worse function. The percentage score is converted to a logit score ranging from -6.66 to 5.39 using a look-up table defined as part of the FRS instrument, where a higher (more positive) logit score indicates better function/less disease severity (5.39 = normal) and a lower (more negative) logit score indicates worse function/greater disease severity (-6.66 = advanced/profound impairment). A decrease in logit score over time reflects clinical progression

Time frame:
baseline to 96 weeks
Reported as:
Least squares mean · score on the scale
Part 1 Double Blind: Clinical Progression as Measured by Frontotemporal Dementia Rating Scale (FRS) Logit Score in Symptomatic Participants
score on the scalePart 1 Blinded - AL001Part 1 Blinded - Placebo
Part 1 Double Blind: Clinical Progression as Measured by Frontotemporal Dementia Rating Scale (FRS) Logit Score in Symptomatic Participants-2.006 (-2.600 to -1.413)-1.925 (-2.431 to -1.420)

Adverse events

Collected over Adverse events (AE) were collected from the screening period (up to 6 weeks prior to Day 1) through 10 weeks after the last dose of study drug, for a total duration of up to 112 weeks (planned) for participants completing the planned Part 1 double-blind period (96 weeks) plus follow-up. For participants in Part 2 (OLE), AE collection continued through 10 weeks after their last dose, up to the date of early study termination or completion for a maximum of an additional 106 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part 1 Blinded - AL0012/72 (2.8%)11/72 (15.3%)27/72 (37.5%)
Part 1 Blinded - Placebo0/46 (0%)3/46 (6.5%)16/46 (34.8%)
Part 2 (OLE Treatment) - AL0011/35 (2.9%)2/35 (5.7%)15/35 (42.9%)
Part 2 (OLE Treatment) - Placebo Switched to AL0010/28 (0%)2/28 (7.1%)11/28 (39.3%)
Most frequent serious events
Showing 10 of 20
Most frequent serious events
EventPart 1 Blinded - AL001Part 1 Blinded - PlaceboPart 2 (OLE Treatment) - AL001Part 2 (OLE Treatment) - Placebo Switched to AL001
Ischaemic cerebral infarctionNervous system disorders0/720/460/351/28
ConstipationGastrointestinal disorders0/720/460/351/28
Urinary tract infectionInfections and infestations0/720/460/351/28
Haemorrhagic strokeNervous system disorders0/720/461/350/28
Invasive ductal breast carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/720/461/350/28
Malignant melanomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/721/460/350/28
Prostatic adenomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/721/460/350/28
Peripheral venous diseaseVascular disorders0/721/460/350/28
Accidental exposure to productInjury, poisoning and procedural complications1/720/460/350/28
Femoral neck fractureInjury, poisoning and procedural complications1/720/460/350/28
Most frequent other events
Showing 10 of 28
Most frequent other events
EventPart 1 Blinded - AL001Part 1 Blinded - PlaceboPart 2 (OLE Treatment) - AL001Part 2 (OLE Treatment) - Placebo Switched to AL001
COVID-19Respiratory, thoracic and mediastinal disorders13/729/462/351/28
Urinary tract infectionInfections and infestations10/728/465/355/28
FallInjury, poisoning and procedural complications11/727/464/350/28
InfluenzaInfections and infestations6/722/463/354/28
InsomniaPsychiatric disorders2/724/464/353/28
FatigueGeneral disorders8/721/461/350/28
Urinary IncontinenceRenal and urinary disorders8/722/460/353/28
HeadacheNervous system disorders3/725/463/350/28
NasopharyngitisInfections and infestations6/723/463/351/28
AnxietyPsychiatric disorders1/722/463/350/28

Baseline characteristics

One symptomatic participant was randomized to placebo but never received study treatment. Of the 102 symptomatic participants that received treatment, 63 received latozinemab and 39 received placebo. Of the 16 participants at-risk, 9 received latozinemab and 7 received placebo. A total of 63 participants continued into Part 2 of the study: 35 participants from the latozinemab group and 28 participants from the placebo group.

Age, Categorical
Age, Categorical(Participants)Part 1 Blinded - AL001Part 1 Blinded - PlaceboTotal
<=18 years000
Between 18 and 65 years493079
>=65 years231639
Sex: Female, Male
Sex: Female, Male(Participants)Part 1 Blinded - AL001Part 1 Blinded - PlaceboTotal
Female402060
Male322658
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Part 1 Blinded - AL001Part 1 Blinded - PlaceboTotal
American Indian or Alaska Native000
Asian112
Native Hawaiian or Other Pacific Islander000
Black or African American000
White6538103
More than one race000
Unknown or Not Reported6713
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Part 1 Blinded - AL001Part 1 Blinded - PlaceboTotal
Hispanic or Latino538
Not Hispanic or Latino613899
Unknown or Not Reported6511
Region of Enrollment
Region of Enrollment(Participants)Part 1 Blinded - AL001Part 1 Blinded - PlaceboTotal
Argentina101
United States151025
United Kingdom415
Portugal5712
Switzerland011
Spain9211
Greece202
Canada213
Netherlands314
Sweden112
Turkey123
Belgium202
Italy201434
Australia022
France448
Germany314
Handedness
Handedness(Participants)Part 1 Blinded - AL001Part 1 Blinded - PlaceboTotal
Left Handed617
Right Handed6645111
Height
Height(Centimeters)Part 1 Blinded - AL001Part 1 Blinded - PlaceboTotal
Mean169.33 ± 8.972168.86 ± 9.626169.15 ± 9.192
Weight
Weight(Kg)Part 1 Blinded - AL001Part 1 Blinded - PlaceboTotal
Mean77.30 ± 14.42978.05 ± 13.55677.59 ± 14.041

1 further baseline measures are reported on the registry.

08

Study locations

44 sites
  • Dignity Health
    Phoenix, Arizona 85013, United States
  • University of California San Diego
    La Jolla, California 92093, United States
  • University of Colorado
    Aurora, Colorado 80045, United States
  • Emory University
    Atlanta, Georgia 30329, United States
  • Indiana University Health Neuroscience Center
    Indianapolis, Indiana 46202, United States
  • University of Kansas Alzheimer's Disease Center
    Fairway, Kansas 66205, United States
  • Johns Hopkins University School of Medicine
    Baltimore, Maryland 21205, United States
  • Mayo Comprehensive Cancer Center - PPDS
    Rochester, Minnesota 55905, United States
  • Irving Institute for Clinical and Translational Research
    New York, New York 10032, United States
  • University Of Cincinnati Gardner Neuroscience institute
    Cincinnati, Ohio 45219, United States
  • Oregon Health and Science University
    Portland, Oregon 97239, United States
  • University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37232, United States
  • Houston Methodist Institute for Academic Medicine
    Houston, Texas 77030, United States
  • Fundación Para La Lucha Contra Las Enfermedades Neurológicas de La Infancia
    Buenos Aires, C1428AQK, Argentina
  • Box Hill Hospital
    Box Hill, 3128, Australia
  • The Queen Elizabeth Hospital
    Woodville, 5011, Australia
  • UZ Leuven
    Leuven, Vlaams Brabant 3000, Belgium
  • The University of Western Ontario
    London, N6A 3K7, Canada
  • Sunnybrook Research Institute - University of Toronto
    Toronto, M4N 3M5, Canada
  • CHU de Bordeaux
    Bordeaux, 33404, France
  • CHRU Lille
    Lille, 59000, France
  • Groupe Hospitalier Pitié Salpétrière
    Paris, 75651, France
  • Uniklinik Köln
    Cologne, 50937, Germany
  • Universitätsklinikum Ulm
    Ulm, 89075, Germany
  • Eginitio University General Hospital of Athens - 1st University Neurology Clinic
    Athens, Attica 115 28, Greece
  • University General Hospital of Alexandroupolis - Department of Neurology
    Alexandroupoli, Evros 68100, Greece
  • Nuovo Ospedale Civile S. Agostino-Estense di Baggiovara
    Baggiovara, 41126, Italy
  • ASST degli Spedali Civili di Brescia - Spedali Civili di Brescia
    Brescia, 25125, Italy
  • IRCCS - Centro S. Giovanni di Dio Fatebenefratelli
    Brescia, 25125, Italy
  • Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico
    Milan, 20122, Italy
  • Fondazione IRCCS Di Rilievo Nazionale Istituto Nazionale Neurologico Carlo Besta
    Milan, 20133, Italy
  • PIA Fondazione Panico
    Tricase, 73039, Italy
  • Erasmus MC
    Rotterdam, 3000 CA, Netherlands
  • Centro Hospitalar do Porto - Hospital de Santo António
    Porto, Porto District 4099-001, Portugal
  • Centro Hospitalar E Universitário de Coimbra EPE
    Coimbra, 3000-075, Portugal
  • Centro Hospitalar de Lisboa Norte, EPE - Hospital de Santa Maria
    Lisbon, 1649-035, Portugal
  • Hospital CUF Descobertas
    Lisbon, 1998-018, Portugal
  • Hospital Clinic de Barcelona
    Barcelona, 08036, Spain
  • Hospital Universitario de Donostia
    Donostia / San Sebastian, 20014, Spain
  • Karolinska Universitetssjukhuset Huddinge - PPDS
    Huddinge, 141 57, Sweden
  • Felix Platter Spital
    Basel, 4055, Switzerland
  • Istanbul University Medical Faculty
    Istanbul, Fatih 34093, Turkey (Türkiye)
  • University College London
    London, WC1E 6BT, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2020 to primary completion in Sep 2025, 61 months.

Results were first posted in Sep 2026, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 23, 2020
First posted
May 5, 2020
StartActual
Jul 23, 2020
Primary completionActual
Sep 1, 2025
CompletionActual
Jan 6, 2026
Results first posted
Sep 21, 2026
Last update
Sep 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04374136
Lead sponsor
Alector Inc.
Collaborators
GlaxoSmithKline
Responsible party
Sponsor
First posted
May 5, 2020
Start date
Jul 23, 2020
Primary completion
Sep 1, 2025
Completion
Jan 6, 2026
Results posted
Sep 21, 2026
Last update
Sep 21, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion